Back

Risk of atrial fibrillation development of sodium-glucose co-transporter 2 inhibitor and thiazolidinedione treatment among patients with type 2 diabetes

30 August 2021 (07:24 - 07:33)
Organised by:
Congress Presentation Part of: Clinical questions: management of patients with atrial fibrillation Prevalence and Incidence of Atrial Fibrillation ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Associate Professor Yoo Ri Kim

Chonnam National University Hospital, Gwangju (Korea (Republic of))

4 More presentations in this session

Presentation thumbnail
Early Rhythm-Control Therapy in Patients with Atrial Fibrillation: A nationwide cohort study
Doctor T. Chao (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Oral anticoagulation in atrial fibrillation patients at intermediate risk of stroke: a nationwide registry-based cohort (Atrial Fibrillation in Norway - AFNOR)
Doctor M. Anjum (Baerum, NO)
Abstract Slides Video
Presentation thumbnail
Are the results of the RATE-AF trial reproducible in daily practice? Clinical outcomes with digoxin vs beta-blocker for heart rate control in permanent atrial fibrillation
Professor L. Fauchier (Tours, FR)
Abstract Slides Video
Presentation thumbnail
Low incidence of major complications after the first six hours post-atrial fibrillation ablation - same-day discharge safe and feasible in most patients
Doctor A. Paul Nordin (Stockholm, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Clinical questions: management of patients with atrial fibrillation

The Event

Event poster

ESC Congress 2021 - The Digital Experience

30 August 2021 07:24 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources